Over the past thirty years, genetic testing for inherited pathogenic variants in the BRCA1 and BRCA2 genes in patients with suspected hereditary breast and ovarian cancer (HBOC) has moved from research to being an established part of breast and ovarian cancer care. Here, BRCA1 is linked to ovarian carcinoma.